These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21481164)

  • 1. The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.
    Smith WR; Ballas SK; McCarthy WF; Bauserman RL; Swerdlow PS; Steinberg MH; Waclawiw MA;
    Pain Med; 2011 May; 12(5):697-705. PubMed ID: 21481164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea and sickle cell anemia: effect on quality of life.
    Ballas SK; Barton FB; Waclawiw MA; Swerdlow P; Eckman JR; Pegelow CH; Koshy M; Barton BA; Bonds DR
    Health Qual Life Outcomes; 2006 Aug; 4():59. PubMed ID: 16942629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.
    Ballas SK; Bauserman RL; McCarthy WF; Castro OL; Smith WR; Waclawiw MA;
    J Pain Symptom Manage; 2010 Dec; 40(6):870-82. PubMed ID: 20864308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
    Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ
    Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cautionary note regarding hydroxyurea in sickle cell disease.
    Vichinsky EP; Lubin BH
    Blood; 1994 Feb; 83(4):1124-8. PubMed ID: 7509209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
    Ballas SK; Connes P;
    Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia.
    Sheehan VA; Crosby JR; Sabo A; Mortier NA; Howard TA; Muzny DM; Dugan-Perez S; Aygun B; Nottage KA; Boerwinkle E; Gibbs RA; Ware RE; Flanagan JM
    PLoS One; 2014; 9(10):e110740. PubMed ID: 25360671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Rankine-Mullings AE; Nevitt SJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
    Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
    Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
    Maier-Redelsperger M; de Montalembert M; Flahault A; Neonato MG; Ducrocq R; Masson MP; Girot R; Elion J
    Blood; 1998 Jun; 91(12):4472-9. PubMed ID: 9616141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological modification of hemoglobin F expression in sickle cell anemia: an update on hydroxyurea studies.
    Charache S
    Experientia; 1993 Feb; 49(2):126-32. PubMed ID: 7680002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
    Charache S; Dover GJ; Moore RD; Eckert S; Ballas SK; Koshy M; Milner PF; Orringer EP; Phillips G; Platt OS
    Blood; 1992 May; 79(10):2555-65. PubMed ID: 1375104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Moore RD; Charache S; Terrin ML; Barton FB; Ballas SK
    Am J Hematol; 2000 May; 64(1):26-31. PubMed ID: 10815784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.